FMP

FMP

Enter

IDXG - Interpace Bioscience...

photo-url-https://images.financialmodelingprep.com/symbol/IDXG.png

Interpace Biosciences, Inc.

IDXG

PNK

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

0.89 USD

-0.03 (-3.37%)

About

ceo

Dr. Thomas W. Burnell Ph.D.

sector

Healthcare

industry

Medical - Diagnostics & Research

exchange

PNK

Description

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

CIK

0001054102

ISIN

US46062X3035

CUSIP

46062X303

Address

Morris Corporate Center 1

Phone

855 776 6419

Country

US

Employee

108

IPO Date

May 20, 1998

Key Executives

Name

Title

Pay

Year Born

Dr. Thomas W. Burnell Ph.D.

President, Chief Executive Officer & Cha...

678.41k

1962

Dr. Nicole Massoll M.D.

Chief Medical Officer

0

N/A

Mr. Patrick Kane

Vice President & Corporate Controller

0

N/A

Dr. Sydney D. Finkelstein M.D.

Chief Scientific Officer

0

N/A

Mr. Christopher McCarthy

Chief Financial Officer

307.04k

1992

Mr. Jody Campbell

Chief Revenue Officer

0

N/A

As of December 31, 2024, the total employee count stands at 108, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep